C&L: Ajay Bansal to manage new Nektar division

Nektar Therapeutics announced a newly-created Diabetes Group and appointed Ajay Bansal, currently the company's CFO, as general manager. The company is initiating a search for a new CFO to replace Bansal, who will serve as interim CFO until a replacement is found.

Cytel has hired John Hallinan as CFO. Hallinan was most recently CFO at Signet Laboratories.

Molecular Insight Pharmaceuticals has named Bob Gallahue, CPA, as CFO and Priscilla Harlan as vice president, corporate communications.

Thomas A. Davis, MD, has joined GenVec as its chief medical officer. Dr. Davis was formerly head, adult hematologic malignancies for the Cancer Therapeutics Evaluation Program at the National Cancer Institute (NCI) and senior director, clinical sciences at Medarex.

Ian D. Malcolm has joined Exelixis to serve as vice president of strategic marketing. Malcolm joined Exelixis from Sanofi-Aventis where he most recently served as head of oncology new products and business opportunities.

M. Lynn Smiley, MD, has been named chief medical officer of Inspire Pharmaceuticals. She had been senior vice president of regulatory affairs, compliance, and drug safety at Trimeris.

David H. Persing, MD, PhD, will join Cepheid as executive vice president, chief medical and technical officer with responsibility for research and development. Dr. Persing most recently held the position of senior vice president and chief scientific officer at Corixa.

Fujirebio Diagnostics named Monte W. Wiltse as its new vice president of sales and marketing. Prior to joining FDI, Wiltse held several senior-level marketing management positions with Bayer Healthcare Diagnostics where he was responsible for molecular testing systems and the oncology immunoassay reagent product line.

Magellan Biosciences has named Darren Braccia the vice president of business development. Braccia comes to Magellan from Vertex Pharmaceuticals, where he most recently served as associate director, business development.

Chembio Diagnostics has named Dr. James J. Koziarz to its newly formed advisory board.

David K. Stone, a member of Oscient Pharmaceuticals' board since 2001, will succeed David B. Singer as chairman of the board.

Applied NeuroSolutions, named Jay B. Langner, who has served as chairman of Montefiore Medical Center, to the company's board of directors, replacing Preston Tsao, who resigned for personal reasons.

Judith A. Hemberger, PhD, has been appointed to Renovis' board of directors.

Osteologix has appointed Bobby W. Sandage, Jr., PhD, to the company's board of directors.

AVANIR Pharmaceuticals has elected David J. Mazzo, PhD, to the company's board of directors.

Bioheart has elected David Gury, former chairman, founding CEO and president of Nabi Biopharmaceuticals, to its board of directors.

Caraco Pharmaceutical Laboratories appointed John D. Crissman, MD, and Madhava Reddy as independent directors.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.